← Taiwan Stock Snapshot Database

Home / Indicator library / Biotechnology and Medical Care / Lotus Pharm (1795) overview

Lotus Pharm (1795) stock overview

Valuation, financials, growth, ownership, events, dividends, models and adjusted prices for Lotus Pharm, on one page

中文版 (Chinese)

Lotus Pharm (1795) snapshot, key figures

Price / earnings
12.72x
Price / book
1.97x
Dividend yield
1.50%
Revenue YoY (2026-08)
81.7%
Monthly revenue (2026-08)
TWD 2.11bn
Sector
Biotechnology and Medical Care
Listing venue
Taiwan Stock Exchange
Values above are the official-source snapshot for Lotus Pharm (1795) on 2026-09-17. We do not chase live quotes. Every trading day is frozen as its own point-in-time vintage, so a backtest reading this data sees only what was actually knowable that day, with no look-ahead bias. Missing values stay blank. Nothing is interpolated or extrapolated.

Lotus Pharm (1795): where today sits in the past year

Current value against the 2025-09-17 to 2026-09-17 range, built from 243 frozen daily vintages.

Price / earnings12.72x20th percentile of the past year
10.25xmedian 13.71x20.17x
Price / book1.97x5th percentile of the past year
1.89xmedian 2.50x4.30x
Dividend yield1.50%50th percentile of the past year
1.09%median 1.51%3.05%
The marker is today's value; the faint tick is the one-year median. Every point in this range is the number as it was published on its own date, never a restated figure, so the percentile is what a reader on that day could actually have computed. Ratios at or below zero are excluded rather than treated as cheap. Tickers with fewer than 60 observed dates get no range at all.
That is this ticker against its own past. The other axis — where the same readings sit across the whole market on the same day — is directly below; the two can point in different directions, so both are worth reading. The full decile structure lives on the market P/E, P/B and dividend yield pages.

Lotus Pharm (1795): where today sits across the whole market

The same figures read against every other listed company on 2026-09-17, rather than against this ticker's own history.

Price / earnings12.72x28th percentile market-wide
10th pct8.98xmarket median17.99x90th pct68.89x
Price / book1.97x60th percentile market-wide
10th pct0.70xmarket median1.64x90th pct5.23x
Dividend yield1.50%35th percentile market-wide
10th pct0.00%market median2.71%90th pct6.76%
Valid sample per metric: price / earnings 1,542, price / book 1,078, dividend yield 1,734. The three metrics are sampled independently rather than intersected, so the denominators differ — an intersection would turn every percentile into the percentile of whichever companies happen to disclose all three, a population nobody is asking about. Ratios at or below zero are excluded rather than counted as cheap; a zero dividend yield is kept because paying nothing is a real observation. The bar spans the 10th to 90th percentile, not the full range, because a handful of four-digit multiples would otherwise flatten every other company into the left edge; the percentile itself is computed on the full population and is unaffected.
The full decile structure behind these percentiles is on the market P/E, P/B and dividend yield distribution pages.
Checkup signals: 4 green / 2 amber / 1 red Full checkup →
Financial quality (F-score)Valuation percentile (P/E vs market)Revenue momentum (latest month, YoY)Ownership concentration (1,000-lot holders, weekly)Insider pledge ratioInsider disposal filings (last 60 days)Buyback announcements (last 12 months)

Seven-dimension checkup for this ticker →

Valuation river

→
P/E 12.72x · P/B 1.97x · market rank 28th percentile across the market

Financial quality

→
F-score quality checks passed: 2 of 6 checks that could be computed

Revenue growth

→
Monthly revenue, 2026-08: +81.7% year on year

Ownership structure

→
Large holders at 52.50%, +0.02 points week on week · insider pledge 0.0% as of 2026-08-31

Events, last 90 days

→
Loading…

Yield river

→
Cash dividend yield in the latest snapshot: 1.50%

Valuation models

→
Loading…

Adjusted-price candles

→
Loading…

1795: common questions

What is 1795's P/E ratio?

1795 traded at a price-to-earnings ratio of 12.72x in the official-source snapshot dated 2026-09-17. That figure is frozen as a point-in-time vintage, so a backtest reading it sees only what was knowable that day.

What is 1795's price-to-book ratio?

1795's price-to-book ratio was 1.97x on 2026-09-17, taken as-is from the official public source.

What is 1795's dividend yield?

1795's cash dividend yield was 1.50% on 2026-09-17. Historical dividend policy and gap-fill records are available on the same page.

How fast is 1795's revenue growing?

1795 reported 81.7% year-on-year monthly revenue growth for 2026-08, from the official monthly revenue filing.

Is 1795's price / earnings high or low right now?

1795's price / earnings is 12.72x, which is below its one-year median of 13.71x and sits at the 20th percentile of the 10.25–20.17x range observed over the last 243 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.

Is 1795's price / book high or low right now?

1795's price / book is 1.97x, which is below its one-year median of 2.50x and sits at the 5th percentile of the 1.89–4.30x range observed over the last 243 snapshot dates. Each of those dates is a frozen point-in-time vintage, so the range contains no restated or back-filled values.

How does 1795's price / earnings compare with the rest of the Taiwan market?

1795's price / earnings of 12.72x is below the market median of 17.99x and sits at the 28th percentile of the 1,542 tickers carrying a valid reading that day — 1,112 of them read higher. This is the cross-section on a single frozen date, a different question from where the ticker sits against its own past year.

How does 1795's price / book compare with the rest of the Taiwan market?

1795's price / book of 1.97x is above the market median of 1.64x and sits at the 60th percentile of the 1,078 tickers carrying a valid reading that day — 433 of them read higher. This is the cross-section on a single frozen date, a different question from where the ticker sits against its own past year.

Other Biotechnology and Medical Care tickers

159 Taiwan-listed tickers sit in this sector. See the full Biotechnology and Medical Care table.

Everything on this page is either the official public source shown as-is, or a transparent derivation you can reproduce. The free tier covers 2330 in full as a reference case; on other tickers some blocks are paid-tier. What we sell is data and tooling, not investment advice, not stock tips, and not a promise of returns.